Working… Menu

p53 Activation in Platinum-Resistant High Grade Serous Ovarian Cancer, a Study of PLD With APR-246

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03268382
Recruitment Status : Completed
First Posted : August 31, 2017
Last Update Posted : October 10, 2019
Information provided by (Responsible Party):
Aprea Therapeutics